Michael Hayden is the founder of Prilenia. Prilenia has raised $85M in total funding. Latest round: Series A. Based in Israel, Netherlands.
Michael Hayden, MD, PhD, is the CEO and founder of Prilenia Therapeutics, a clinical-stage biotechnology company. He leads the company's efforts with its lead asset, pridopidine, which is in Phase 3 trials for Huntington's disease and a Phase 2/3 trial for ALS. Hayden has been with Prilenia since its founding in 2018.
Full founder directory · Investor directory · Company funding database · Fundraising library